ArticleJournal of acquired immune deficiency syndromes (1999)2026
Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020.
Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIsoniazid preventive therapy (IPT) is recommended for the treatment of latent tuberculosis (TB) infection and is beneficial for persons living with HIV (PLHIV) even after initiation of antiretroviral therapy (ART). After the roll out of dolutegravir (DTG)-based ART in 2018, the Uganda Ministry of Health rapidly expanded IPT coverage among PLHIV. We assessed if concomitant IPT and DTG administration (C-IPT) increased the risk of IPT-related adverse drug reactions (ADRs) compared with delayed IPT administration (D-IPT).
methodsWe abstracted data from medical records of PLHIV aged ≥18 years who initiated IPT between July 2019 and March 2020 at an HIV clinic in Kampala. IPT-ADR incidence was calculated from IPT initiation to first ADR or censoring, expressed as the number of ADRs per person-years at risk. Kaplan-Meier survival analysis and the log-rank test were used to compare ADR risk between groups. A Cox proportional hazards model estimated the adjusted effect of C-IPT on ADR incidence, and robustness was evaluated using Poisson regression with standard errors.
resultsWe analyzed data from 336 patients on DTG-based ART and IPT, 58% were male, with a median age of 46 years (IQR; 38-54), and 66.7% had no history of comorbidities. Overall, 193 (57.4%) reported at-least 1 IPT-related ADR during 114.72-person years of follow-up. After adjusting for age, HIV-1 viral load, and history of comorbidities, C-IPT was associated a significantly higher risk of IPT-related ADRs compared with D-IPT (adjusted Hazard Ratio 1.63, 95% CI: 1.17 to 2.26, P < 0.01). There was no difference in the proportion of patients who discontinued IPT because of ADRs in either group (2.2%, 2/95 vs. 4.2%, 10/241, P = 0.36).
conclusionConcomitant initiation of IPT and DTG-based ART was associated with a higher risk of ADRs but did not increase IPT discontinuation. Enhanced clinical monitoring is warranted for patients initiating both therapies to facilitate early detection and management of ADRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.